James W. Janetka

Citeras av

	Alla	Sedan 2019
Citat	5949	2647
h-index	43	27
i10-index	72	50

560

280

140

420

199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202418 22 19 26 12 31 12 24 34 38 42 61 151 144 199 298 331 283 310 372 362 437 495 462 558 477 461 193

Offentlig åtkomst

Visa alla

34 artiklar

5 artiklar

tillgänglig

inte tillgänglig

Enligt krav från finansiärer

Medförfattare

Laurel Mydock-McGraneFimbrion TherapeuticsVerifierad e-postadress på fimbrion.com
Scott WildmanUniversity of Wisconsin-MadisonVerifierad e-postadress på wisc.edu
Vishnu C. Damalanka, Ph.DResearch InstructorVerifierad e-postadress på wustl.edu
Jeremy GreenGreen Chemistry Consulting LLCVerifierad e-postadress på hms.harvard.edu
Vasilios Kalas, MD, PhDMcGaw Medical Center of Northwestern UniversityVerifierad e-postadress på northwestern.edu
Amarendar MaddiralaWashington University in St.Louis School of MedicineVerifierad e-postadress på wustl.edu
Dorin ToaderDirector at Mersana TherapeuticsVerifierad e-postadress på mersana.com
Thomas J. HannanWashington UniversityVerifierad e-postadress på wustl.edu
Jeffrey P Henderson, MD, PhD, FIDSADivision of Infectious Diseases, Department of Medicine, Washington UniversityVerifierad e-postadress på wustl.edu
Partha KarmakarAbzena, Bristol, PA, USAVerifierad e-postadress på wustl.edu
Michael E. HibbingFimbrion Therapeutics. Inc.Verifierad e-postadress på Fimbrion.com
Daved H. FremontDepartment of Pathology and Immunology, Washington UniversityVerifierad e-postadress på wustl.edu
L. David SibleyWashington University in St. LouisVerifierad e-postadress på wustl.edu
Makedonka MitrevaProfessor of Medicine, Washington University School of MedicineVerifierad e-postadress på wustl.edu
Cassie JarvisSenior Scientist, MerckVerifierad e-postadress på merck.com
Ursula GermannOnKognos Scientific Consulting & ServicesVerifierad e-postadress på onkognos.com
Marc JacobsVertex PharmaceuticalsVerifierad e-postadress på vrtx.com
Robert GalemmoVerge GenomicsVerifierad e-postadress på galemmoconsulting.com
Bin YangExecutive Director, Medicinal Chemistry, Kymera TherapeuticsVerifierad e-postadress på kymeratx.com
Stephanie SpringerFDAVerifierad e-postadress på fda.hhs.gov

Följ

James W. Janetka

Professor, Washington University School of Medicine

Verifierad e-postadress på wustl.edu - Startsida

cancer infectious diseases medicinal chemistry proteases lectins


Titel Sortera efter citat Sortera efter år Sortera efter titel	Citeras av Citeras av	År
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies SD Zabludoff, C Deng, MR Grondine, AM Sheehy, S Ashwell, BL Caleb, ... Molecular cancer therapeutics 7 (9), 2955-2966, 2008	446	2008
Treatment and prevention of urinary tract infection with orally active FimH inhibitors CK Cusumano, JS Pinkner, Z Han, SE Greene, BA Ford, JR Crowley, ... Science translational medicine 3 (109), 109ra115-109ra115, 2011	348	2011
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics CX Ma, JW Janetka, H Piwnica-Worms Trends in molecular medicine 17 (2), 88-96, 2011	305	2011
Structure-based drug design and optimization of mannoside bacterial FimH antagonists Z Han, JS Pinkner, B Ford, R Obermann, W Nolan, SA Wildman, D Hobbs, ... Journal of medicinal chemistry 53 (12), 4779-4792, 2010	298	2010
Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist CN Spaulding, RD Klein, S Ruer, AL Kau, HL Schreiber, ZT Cusumano, ... Nature 546 (7659), 528-532, 2017	268	2017
MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A AG Rocha, A Franco, AM Krezel, JM Rumsey, JM Alberti, WC Knight, ... Science 360 (6386), 336-341, 2018	231	2018
Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control AM Aronov, Q Tang, G Martinez-Botella, GW Bemis, J Cao, G Chen, ... Journal of medicinal chemistry 52 (20), 6362-6368, 2009	185	2009
Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides Z Han, JS Pinkner, B Ford, E Chorell, JM Crowley, CK Cusumano, ... Journal of medicinal chemistry 55 (8), 3945-3959, 2012	157	2012
Dynamic combinatorial chemistry: in drug discovery, bioorganic chemistry, and materials science BL Miller John Wiley & Sons, 2009	155	2009
A FimH Inhibitor Prevents Acute Bladder Infection and Treats Chronic Cystitis Caused by Multidrug-Resistant Uropathogenic Escherichia coli ST131 M Totsika, M Kostakioti, TJ Hannan, M Upton, SA Beatson, JW Janetka, ... The Journal of infectious diseases 208 (6), 921-928, 2013	152	2013
Pyrazole compositions useful as inhibitors of ERK M Hale, J Janetka, F Maltais, J Cao US Patent 6,784,195, 2004	138	2004
Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors AM Aronov, C Baker, GW Bemis, J Cao, G Chen, PJ Ford, UA Germann, ... Journal of medicinal chemistry 50 (6), 1280-1287, 2007	137	2007
Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice PS Guiton, CK Cusumano, KA Kline, KW Dodson, Z Han, JW Janetka, ... Antimicrobial agents and chemotherapy 56 (9), 4738-4745, 2012	129	2012
Pyrazole compositions useful as inhibitors of ERK M Hale, X Xie, J Green, J Cao, C Baker, F Maltais, J Janetka, G Bemis, ... US Patent 6,528,509, 2003	124	2003
Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment BY Owusu, R Galemmo, J Janetka, L Klampfer Cancers 9 (4), 35, 2017	118	2017
Total synthesis of the cyclic biphenyl ether peptides K-13 and OF4949-III via SNAr macrocyclization of peptidyl ruthenium π-arene complexes JW Janetka, DH Rich Journal of the American Chemical Society 119 (28), 6488-6495, 1997	116	1997
Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections L Mydock-McGrane, Z Cusumano, Z Han, J Binkley, M Kostakioti, ... Journal of medicinal chemistry 59 (20), 9390-9408, 2016	109	2016
Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease LK Mydock-McGrane, TJ Hannan, JW Janetka Expert opinion on drug discovery 12 (7), 711-731, 2017	95	2017
Precision antimicrobial therapeutics: the path of least resistance? CN Spaulding, RD Klein, HL Schreiber IV, JW Janetka, SJ Hultgren NPJ biofilms and microbiomes 4 (1), 4, 2018	88	2018
Keeping checkpoint kinases in line: new selective inhibitors in clinical trials S Ashwell, JW Janetka, S Z abludoff Expert opinion on investigational drugs 17 (9), 1331-1340, 2008	87	2008

Systemet kan inte utföra åtgärden just nu. Försök igen senare.

Artiklar 1–20

Citat per år

Dubblettcitat

Sammanfogade citat

Lägg till medförfattareMedförfattare

Följ

Citeras av

Medförfattare